Allianz Asset Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Allianz Asset Management’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-501,401	Closed	-$30M	–	2854
2019 Q4	$30M	Buy	501,401 +460,964	+1,140%	+$17.3M	0.03%	608
2019 Q3	$1.13M	Sell	40,437 -60,410	-60%	-$2.06M	﹤0.01%	2072
2019 Q2	$3.82M	Sell	100,847 -2,140	-2%	-$82.2K	﹤0.01%	1624
2019 Q1	$4.02M	Buy	102,987 +23,955	+30%	+$687K	﹤0.01%	1555
2018 Q4	$1.69M	Buy	79,032 +4,191	+6%	+$108K	﹤0.01%	1822
2018 Q3	$2.96M	Buy	74,841 +5,168	+7%	+$193K	﹤0.01%	1798
2018 Q2	$2.66M	Buy	69,673 +13,849	+25%	+$513K	﹤0.01%	1817
2018 Q1	$1.68M	Buy	+55,824	New	+$1.89M	﹤0.01%	2001

Allianz Asset Management's BOLD Position: Q1 2020 in Review

Allianz Asset Management sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 501,401 shares — an estimated $30M sold.

Allianz Asset Management first reported a position in BOLD in Q1 2018 and held it in 8 quarters. The position peaked at $30M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

Allianz Asset Management reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
Allianz Asset Management sold 501,401 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $30M.
Allianz Asset Management first reported a position in Audentes Therapeutics, Inc in Q1 2018 and held it in 8 quarters.
Allianz Asset Management's Audentes Therapeutics, Inc position peaked at $30M in Q4 2019.
0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Allianz Asset Management's 13F filing for Q1 2020, filed 14 May 2020.